Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sarcolysin SCHEMBL414671 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| (R)-Melphalan SCHEMBL5873 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Melphalan SCHEMBL5325132 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Melphalan SCHEMBL563239 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Melphalan SCHEMBL41335 | 0.98 | HIF1A (0.97) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Melphalan SCHEMBL2723742 | 0.98 | HIF1A (0.97) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Sarcolysin SCHEMBL2680958 | 0.98 | HIF1A (0.97) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Melphalan SCHEMBL4150935 | 0.98 | HIF1A (0.97) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Sarcolysin SCHEMBL29061034 | 0.98 | HIF1A (0.97) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Melphalan SCHEMBL11029192 | 0.98 | HIF1A (0.97) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 189803 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4748376-A2 | METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF T CELL REDIRECTING THERAPEUTICS | Janssen Biotech, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122094711-A | Methods for treating multiple myeloma comprising anti-CD 38 antibodies in combination with bortezomib, lenalidomide and dexamethasone | — | 2026-05-26 | — | — | CN | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| CN-122070936-A | Nanometer material based on supermolecule polypeptide-drug coupling prodrug, and preparation method and application thereof | 中国医学科学院生物医学工程研究所 | 2026-05-22 | — | — | CN | claimed |
| US-20260137650-A1 | MODULATORS OF RAR RELATED ORPHAN RECEPTORS (RORs) | 11949098 CANADA INC (CA) | 2026-05-21 | — | — | US | claimed |
| US-20260137686-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| WO-2026106917-A1 | EDIBLE TRANSMUCOSAL DRUG DELIVERY METHOD USING AN INTERMEDIATE CAPSULE AS A TEMPORARY VESSEL | BioPhysics Pharma, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| WO-1984001506-A1 | PHARMACEUTICAL PREPARATIONS FOR USE IN ANTITUMOUR THERAPY | UNIV BIRMINGHAM (GB) | 1984-04-26 | — | — | WO | claimed |
| EP-0095906-A1 | Improvements relating to compounds useful in radiotherapy or chemotherapy | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1983-12-07 | — | — | EP | claimed |
| WO-1983003968-A1 | BRAIN-SPECIFIC DRUG DELIVERY | UNIVERSITY OF FLORIDA (US) | 1983-11-24 | — | — | WO | claimed |
| US-4401592-A | REACTION PRODUCT OF AN ANTIBODY WITH AN ANTIBIOTIC, ANTIMETABOLIC SUBSTANCE OR ALKYLATING AGENT | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1983-08-30 | — | — | US | claimed |
| EP-0083600-A1 | Use of alkaloid derivatives for the manufacture of a medicament for the strengthening of the immune system and for the treatment of viral, bacterial and fungal infections. | NOWICKY WASSILI | 1983-07-20 | — | — | EP | claimed |
| WO-1983000486-A1 | METHOD FOR THE DIAGNOSTIC AND THE THERAPEUTIC TREATMENT OF TUMORS AND/OR INFECTIOUS DISEASES OF ALL SORTS BY THE USE OF ALKALOID COMPOSITIONS OR THE SALTS THEREOF | NOWICKY, WASSYL | 1983-02-17 | — | — | WO | claimed |
| EP-0064040-A1 | Therapeutically active disulphide compounds and their use | PHARMACIA AKTIEBOLAG (SE) | 1982-11-03 | — | — | EP | claimed |
| WO-1982003395-A1 | THERAPEUTICALLY ACTIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | PHARMACIA AB (SE) | 1982-10-14 | — | — | WO | claimed |
| EP-0010964-A1 | Ravidomycin, process of preparation and pharmaceutical compositions containing same | AYERST, MCKENNA AND HARRISON INC. (CA) | 1980-05-14 | — | — | EP | claimed |
| US-4017471-A | ANTITUMOR AGENT | G. D. SEARLE & CO. (EN) | 1977-04-12 | — | — | US | claimed |